___

• 1. Wang Z, Cui X, Hao G, He J. Aberrant expression of PI3K/AKT signaling is involved in apoptosis resistance of hepatocellular carcinoma. Open Life Sci. 2021;16(1):1037-1044. google scholar
• 2. Xie Y, Shi X, Sheng K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019;19(2):783-791. google scholar
• 3. Staal SP, Hartley JW. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med. 1988;167(3):1259-1264. google scholar
• 4. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol. 2005;17(2):150-157. google scholar
• 5. Zhang Z, Yao L, Yang J, Wang Z, Du G. PI3K/Akt and HIF 1 signaling pathway in hypoxia ischemia (Review). Mol Med Rep. 2018;18(4):3547-3554. google scholar
• 6. Linnerth-Petrik NM, Santry LA, Moorehead R, Jücker M, Woot-ton SK, Petrik J. Akt isoform specific effects in ovarian cancer progression. Oncotarget. 2016;7(46):74820-74833. google scholar
• 7. Zhang F, Ding T, Yu L, Zhong Y, Dai H, Yan M. Dexmedetomi-dine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells. J Pharm Pharmacol. 2012;64(1):120-127. google scholar
• 8. Ciuffreda L, Falcone I, Incani UC, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul. 2014;56:66-80. google scholar
• 9. Ojeda L, Gao J, Hooten KG, et al. Critical role of PI3K/Akt/GSK3fi in motoneuron specification from human neural stem cells in response to FGF2 and EGF. PLoS One. 2011;6(8):e23414. doi: 10.1371/journal.pone.0023414. google scholar
• 10. Wyatt LA, Filbin MT, Keirstead HS. PTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neu-ronal progenitor cells. J Comp Neurol. 2014;522(12):2741-2755. google scholar
• 11. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481-507. google scholar
• 12. Zhao S, Fu J, Liu F, Rastogi R, Zhang J, Zhao Y. Small in-terfering RNA directed against CTMP reduces acute traumatic brain injury in a mouse model by activating Akt. Neurol Res. 2014;36(5):483-490. google scholar
• 13. Rana A, Singh S, Sharma R, Kumar A. Traumatic brain in-jury altered normal brain signaling pathways: Implications for novel therapeutics approaches. Curr Neuropharmacol. 2019;17(7):614-629. google scholar
• 14. Marklund N. Rodent Models of Traumatic Brain Injury: Meth-ods and Challenges. In: Kobeissy FH, Dixon CE, Hayes RL, Mondello S, eds. Injury Models of the Central Nervous System. Vol 1462. Methods in Molecular Biology. Springer New York; 2016:29-46. google scholar
• 15. Bryan-Hancock C, Harrison J. The global burden of traumatic brain injury: preliminary results from the Global Burden of Disease Project. Injury Prevention. 2010;16:A17.http://dx.doi.org/10.1136/ip.2010.029215.61 google scholar
• 16. Chen CC, Hung TH, Lee CY, et al. Berberine protects against neuronal damage via suppression of glia-mediated inflamma-tion in traumatic brain injury. PLoS One. 2014;9(12):e115694. doi:10.1371/journal.pone.0115694. google scholar
• 17. Lagraoui M, Sukumar G, Latoche JR, Maynard SK, Dalgard CL, Schaefer BC. Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun. 2017;61:96-109. google scholar
• 18. Nikolaeva I. Targeting the PI3K/Akt/mTOR pathway in trau-matic brain injury and developmental disease (Thesis). 2016. google scholar
• 19. Noshita N, Lewen A, Sugawara T, Chan PH. Evidence of phos-phorylation of Akt and neuronal survival after transient fo-cal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2001;21(12):1442-1450. google scholar
• 20. Park J, Zhang J, Qiu J, et al. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab. 2012;32(2):330-340. google scholar
• 21. Zhao S, Fu J, Liu X, Wang T, Zhang J, Zhao Y. Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats. Neurological Research. 2012;34(4):400-407. google scholar
• 22. Wang G, Jiang X, Pu H, et al. Scriptaid, a novel histone deacety-lase inhibitor, protects against traumatic brain injury via mod-ulation of PTEN and AKT pathway : scriptaid protects against TBI via AKT. Neurotherapeutics. 2013;10(1):124-142. google scholar
• 23. Yu N, Hu S, Hao Z. Benificial effect of stachydrine on the trau-matic brain injury induced neurodegeneration by attenuating the expressions of Akt/mTOR/PI3K and TLR4/NFk-B pathway. Transl Neurosci. 2018;9:175-182. google scholar
• 24. Zhang C, Zhu J, Zhang J, et al. Neuroprotective and anti-apoptotic effects of valproic acid on adult rat cerebral cortex through ERK and Akt signaling pathway at acute phase of trau-matic brain injury. Brain Research. 2014;1555:1-9. google scholar
• 25. Rozas NS, Redell JB, Hill JL, et al. Genetic activation of mTORC1 signaling worsens neurocognitive outcome after trau-matic brain injury. J Neurotrauma. 2015;32(2):149-158. google scholar
• 26. Guo D, Zeng L, Brody DL, Wong M. Rapamycin attenu-ates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS ONE. 2013;8(5):e64078. doi:10.1371/journal.pone.0064078. google scholar
• 27. Zhao L, Wu D, Sang M, Xu Y, Liu Z, Wu Q. Stachydrine ame-liorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through in-hibiting NF-kB and JAK/STAT signaling pathways in rats. Int Immunopharmacol. 2017;48:102-109. google scholar
• 28. He H, Liu W, Zhou Y, et al. Sevoflurane post-conditioning atten-uates traumatic brain injury-induced neuronal apoptosis by pro-moting autophagy via the PI3K/AKT signaling pathway. DDDT. 2018;12:629-638. google scholar
• 29. Gao Y, Li J, Wu L, et al. Tetrahydrocurcumin provides neuro-protection in rats after traumatic brain injury: autophagy and the PI3K/AKT pathways as a potential mechanism. J Surg Res. 2016;206(1):67-76. google scholar
• 30. Miao J, Wang L, Zhang X, et al. Protective effect of aliskiren in experimental ischemic stroke: Up-regulated p-PI3K, p-AKT, Bcl-2 expression, attenuated Bax expression. Neurochem Res. 2016;41(9):2300-2310. google scholar
• 31. Zhang L, Ding K, Wang H, Wu Y, Xu J. Traumatic brain injury-induced neuronal apoptosis is reduced through modulation of PI3K and autophagy pathways in mouse by FTY720. Cell Mol Neurobiol. 2016;36(1):131-142. google scholar
• 32. Wang ZG, Cheng Y, Yu XC, et al. bFGF protects against blood-brain barrier damage through junction protein regulation via PI3K-Akt-Rac1 pathway following traumatic brain injury. Mol Neurobiol. 2016;53(10):7298-7311. google scholar
• 33. Wang C, Hu Z, Zou Y, et al. The post-therapeutic effect of rapamycin in mild traumatic brain-injured rats ensuing in the upregulation of autophagy and mitophagy. Cell Biol Int. 2017;41(9):1039-1047. google scholar
• 34. Sun J, Nan G. The extracellular signal-regulated kinase 1/2 path-way in neurological diseases: A potential therapeutic target (Re-view). Int J Mol Med. 2017;39(6):1338-1346. google scholar
• 35. Zhang P, Zhang L, Zhu L, et al. The change tendency of PI3K/Akt pathway after spinal cord injury. Am J Transl Res. 2015;7(11):2223-2232. google scholar
• 36. Yu WR, Fehlings MG. Fas/FasL-mediated apoptosis and inflam-mation are key features of acute human spinal cord injury: impli-cations for translational, clinical application. Acta Neuropathol. 2011;122(6):747-761. google scholar
• 37. Saxena T, Loomis KH, Pai SB, et al. Nanocarrier-mediated inhibition of macrophage migration inhibitory factor atten-uates secondary injury after spinal cord injury. ACS Nano. 2015;9(2):1492-1505. google scholar
• 38. Calvo M, Zhu N, Grist J, Ma Z, Loeb JA, Bennett DLH. Fol-lowing nerve injury neuregulin-1 drives microglial prolifera-tion and neuropathic pain via the MEK/ERK pathway. Glia. 2011;59(4):554-568. google scholar
• 39. Renfu Q, Rongliang C, Mengxuan D, et al. Anti-apoptotic signal transduction mechanism of electroacupuncture in acute spinal cord injury. Acupunct Med. 2014;32(6):463-471. google scholar
• 40. Zhang L, Gu S, Zhao C, Wen T. Combined treatment of neurotrophin-3 gene and neural stem cells is propitious to functional recovery after spinal cord injury. Cell Transplant. 2007;16(5):475-481. google scholar
• 41. Peviani M, Tortarolo M, Battaglia E, Piva R, Bendotti C. Specific induction of Akt3 in spinal cord motor neurons is neuroprotec-tive in a mouse model of familial amyotrophic lateral sclerosis. Mol Neurobiol. 2014;49(1):136-148. google scholar
• 42. Zhao R, Wu X, Bi XY, Yang H, Zhang Q. Baicalin at-tenuates blood-spinal cord barrier disruption and apoptosis through PI3K/Akt signaling pathway after spinal cord injury. Neural Regen Res. 2022;17(5):1080-1087. google scholar
• 43. Wang X, Jiang C, Zhang Y, et al. The promoting effects of activated olfactory ensheathing cells on angiogenesis after spinal cord injury through the PI3K/Akt pathway. Cell Biosci. 2022;12(1):23. doi:10.1186/s13578-022-00765-y. google scholar
• 44. Zheng Z, Zeng Y, Zhu X, et al. ApoM-S1P modulates Ox-LDL-induced inflammation through the PI3K/Akt signaling pathway in HUVECs. Inflammation. 2019;42(2):606-617. google scholar
• 45. Zhu GS, Tang LY, Lv DL, Jiang M.Total flavones of abel-moschus manihot exhibits pro-angiogenic activity by activat-ing the VEGF-A/VEGFR2-PI3K/Akt signaling Axis. Am J Chin Med. 2018;46(3):567-583. google scholar
• 46. Zhang X, Zhao F, Zhao JF, Fu HY, Huang XJ, Lv BD. PDGF-mediated PI3K/AKT/3-catenin signaling regulates gap junc-tions in corpus cavernosum smooth muscle cells. Exp Cell Res. 2018;362(2):252-259. google scholar
• 47. Choi AR, Jeong MH, Hong YJ, et al. Clinical characteristics and outcomes in acute myocardial infarction patients with versus without any cardiovascular risk factors. Korean J Intern Med. 2019;34(5):1040-1049. google scholar
• 48. Golforoush P, Yellon DM, Davidson SM. Mouse models of atherosclerosis and their suitability for the study of my-ocardial infarction. Basic Res Cardiol. 2020;115(6):73. doi: 10.1007/s00395-020-00829-5. google scholar
• 49. Sabatine MS, Braunwald E. Thrombolysis in myocardial infarc-tion (TIMI) study group: JACC focus seminar 2/8. J Am Coll Cardiol. 2021;77(22):2822-2845. google scholar
• 50. Zhang Q, Wang L, Wang S, et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7(1):78. doi:10.1038/s41392-022-00925-z. google scholar
• 51. Feng L, Li B, Xi Y, Cai M, Tian Z. Aerobic exercise and re-sistance exercise alleviate skeletal muscle atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with myocardial infarction. Am J Physiol Cell Physiol. 2022;322(2):C164-C176. google scholar
• 52. Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y. Targeting Akt in cancer for precision therapy. J Hematol Oncol. 2021;14(1):128. doi:10.1186/s13045-021-01137-8. google scholar
• 53. Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular dis-ease. Cardiovasc Ther. 2011;29(1):29-36. google scholar
• 54. Mo XG, Chen QW, Li XS, et al. Suppression of NHE1 by small interfering RNA inhibits HIF-1a-induced angiogenesis in vitro via modulation of calpain activity. Microvasc Res. 2011;81(2):160-168 google scholar
• 55. Gao W, Chang G, Wang J, et al. Inhibition of K562 leukemia an-giogenesis and growth by selective Na+/H+ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF. Leuk Res. 2011;35(11):1506-1511. google scholar
• 56. Liang X, Ding Y, Lin F, et al. Overexpression of ERBB4 re-juvenates aged mesenchymal stem cells and enhances angio-genesis via PI3K/AKT and MAPK/ERK pathways. FASEB J. 2019;33(3):4559-4570. google scholar
• 57. Fan J, Xu W, Nan S, Chang M, Zhang Y. MicroRNA-384-5p promotes endothelial progenitor cell proliferation and angio-genesis in cerebral ischemic stroke through the delta- likeli-gand 4-mediated Notch signaling pathway. Cerebrovasc Dis. 2020;49(1):39-54. google scholar
• 58. Du M, Shan J, Feng A, Schmull S, Gu J, Xue S. Oestrogen receptor fi activation potects against myocardial infarction via Notch1signalling. Cardiovasc Drugs Ther. 2020;34(2):165-178. google scholar
• 59. Huang H, Huang F, Huang JP. Transplantation of bone mar-row derived endothelial progenitor cells overexpressing Delta like 4 enhances functional neovascularization in ischemic my-ocardium. Mol Med Rep. 2013;8(5):1556-1562. google scholar
• 60. Zhou XL, Fang YH, Wan L, et al. Notch signaling inhibits cardiac fibroblast to myofibroblast transformation by antagonizing TGF-fi1/Smad3 signaling. J Cell Physiol. 2019;234(6):8834-8845. google scholar
• 61. Yao Q, Renault MA, Chapouly C, et al. Sonic hedgehog medi-ates a novel pathway of PDGF-BB-dependent vessel maturation. Blood. 2014;123(15):2429-2437. google scholar
• 62. Li M, Zheng H, Han Y, et al. LncRNA Snhg1-driven self-reinforcing regulatory network promoted cardiac regen-eration and repair after myocardial infarction. Theranostics. 2021;11(19):9397-9414. google scholar
• 63. Baraka SA, Tolba MF, Elsherbini DA, El-Naga RN, Awad AS, El-Demerdash E. Rosuvastatin and low-dose carvedilol combi-nation protects against isoprenaline-induced myocardial infarc-tion in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. Clin Exp Pharmacol Physiol. 2021;48(10):1358-1370. google scholar
• 64. Tan SH, Loo SJ, Gao Y, et al. Thymosin fi4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction. Theranostics. 2021;11(16):7879-7895. google scholar
• 65. Luo W, Gong Y, Qiu F, et al. NGF nanoparticles enhance the po-tency of transplanted human umbilical cord mesenchymal stem cells for myocardial repair. Am J Physiol Heart Circ Physiol. 2021;320(5):H1959-H1974. google scholar
• 66. Gnecchi M, He H, Noiseux N, et al. Evidence support-ing paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20(6):661-669. google scholar
• 67. Li X, Zhang H, An G, et al. S-Nitrosylation of Akt by organic nitrate delays revascularization and the recovery of cardiac func-tion in mice following myocardial infarction. J Cell Mol Med. 2021;25(1):27-36. google scholar
• 68. Li S, Wang Y, Zhao C, et al. Akt inhibitor deguelin aggravates inflammation and fibrosis in myocarditis. Iran J Basic Med Sci. 2019;22(11):1275-1282. google scholar
• 69. Zhang Q, Hu L qun, Li H qi, Wu J, Bian N na, Yan G. Beneficial effects of andrographolide in a rat model of autoimmune my-ocarditis and its effects on PI3K/Akt pathway. Korean J Physiol Pharmacol. 2019;23(2):103. google scholar
• 70. Liu HS, Zhang J, Guo JL, Lin CY, Wang ZW. Phosphoinosi-tide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice. Curr Res Transl Med. 2016;64(1):21-27. google scholar
• 71. Song Y, Ge W, Cai H, Zhang H. Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting the phosphatidylinositol 3 kinase/Akt/nuclear factor-^B pathway. J Cardiovasc Pharmacol Ther. 2013;18(6):560-569. google scholar
• 72. Chen Z, Yang L, Liu Y, et al. LY294002 and Rapamycin pro-mote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway. Mol Cell Biochem. 2014;385(1-2):169-177. google scholar
• 73. Liu HS, Zhang J, Guo JL, Lin CY, Wang ZW. Phosphoinosi-tide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice. Curr Res Transl Med. 2016;64(1):21-27. google scholar
• 74. Ouyang S, Zeng Q, Tang N, et al. Akt-1 and Akt-2 differen-tially regulate the development of experimental autoimmune en-cephalomyelitis by controlling proliferation of thymus-derived regulatory T cells. J Immunol. 2019;202(5):1441-1452. google scholar
• 75. Chang H, Li X, Cai Q, et al. The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells. Int J Mol Med. 2017;40(1):182-192. google scholar
• 76. Henao-Martmez AF, Agler AH, Watson AM, et al. AKT net-work of genes and impaired myocardial contractility during murine acute Chagasic myocarditis. Am J Trop Med Hyg. 2015;92(3):523-529. google scholar
• 77. Henao-Martmez AF, Parra-Henao G. Murine heart gene ex-pression during acute Chagasic myocarditis. Genom Data. 2015;4:76-77. google scholar
• 78. He H, Chang X, Gao J, Zhu L, Miao M, Yan T. Salidroside mitigates sepsis-induced myocarditis in rats by regulating IGF-1/PI3K/Akt/GSK-3p signaling. Inflammation. 2015;38(6):2178-2184. google scholar
• 79. Li Q, Li Y, Li J, et al. FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1a/CEACAM5 functional axis. Int J Biol Sci. 2018;14(7):726-735. google scholar
• 80. Hussain I, Waheed S, Ahmad KA, Pirog JE, Syed V. Scutel-laria baicalensis targets the hypoxia-inducible factor-1a and enhances cisplatin efficacy in ovarian cancer. J Cell Biochem. 2018;119(9):7515-7524. google scholar
• 81. Fu Q, Gao L, Fu X, Meng Q, Lu Z. Scutellaria baicalensis inhibits Coxsackievirus B3-induced myocarditis via AKT and p38 pathways. J Microbiol Biotechnol. 2019;29(8):1230-1239. doi:10.4014/jmb.1904.04050. google scholar
• 82. Chen HW, Lin AH, Chu HC, et al. Inhibition of TNF-a-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway. J Nat Prod. 2011;74(11):2408-2413. google scholar
• 83. Lu CY, Yang YC, Li CC, Liu KL, Lii CK, Chen HW. An-drographolide inhibits TNFa-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem Pharmacol. 2014;91(1):40-50. google scholar
• 84. Shioi T. The conserved phosphoinositide 3-kinase pathway de-termines heart size in mice. EMBO J. 2000;19(11):2537-2548. google scholar
• 85. Shiojima I. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108-2118. google scholar
• 86. Ulici V, Hart J. Chordoma. Arch Pathol Lab Med. 2022;146(3):386-395. google scholar
• 87. Williams BJ, Raper DMS, Godbout E, et al. Diagnosis and treat-ment of chordoma. J Natl Compr Canc Netw. 2013;11(6):726-731. google scholar
• 88. Rinner B, Weinhaeusel A, Lohberger B, et al. Chor-doma characterization of significant changes of the DNA methylation pattern. PLoS One. 2013;8(3):e56609. doi:10.1371/journal.pone.0056609. google scholar
• 89. Tamborini E, Virdis E, Negri T, et al. Analysis of receptor ty-rosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol. 2010;12(8):776-789. google scholar
• 90. Dewaele B, Maggiani F, Floris G, et al. Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res.2011;1(1):4. google scholar
• 91. Shalaby A, Presneau N, YeH, et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol. 2011;223(3):336-346. google scholar
• 92. Choy E, MacConaill LE, Cote GM, et al. Genotyping cancer-associated genes in chordoma identifies mutations in onco-genes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS One. 2014;9(7):e101283. doi:10.1371/journal.pone.0101283. google scholar
• 93. Tauziede-Espariat A, Bresson D, Polivka M, et al. Prognostic and therapeutic markers in Chordomas: A study of 287 tumors. J Neuropathol Exp Neurol. 2016;75(2):111-120. google scholar
• 94. Tarpey PS, Behjati S, Young MD, et al. The driver land-scape of sporadic chordoma. Nat Commun. 2017;8(1):890.doi: 10.1038/s41467-017-01026-0. google scholar
• 95. Meng T, Jin J, Jiang C, et al.Molecular targeted therapy in the treatment of Chordoma: A systematic review. Front Oncol. 2019;9:30. doi:10.3389/fonc.2019.00030. google scholar
• 96. de Castro CV, Guimaraes G, Aguiar S, et al. Tyrosine kinase re-ceptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. Hum Pathol. 2013;44(9):1747-1755. google scholar
• 97. Wu Z, Wang L, Guo Z, et al. Experimental study on differences in clivus chordoma bone invasion: an iTRAQ-based quantitative proteomic analysis. PLoS One. 2015;10(3):e0119523.doi:10.1371/journal.pone.0119523. google scholar
• 98. Chen K, Mo J, Zhou M, et al. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol. 2014;31(4):886.doi:10.1007/s12032-014-0886-7. google scholar
• 99. Scheipl S, Barnard M, Cottone L, et al. EGFR inhibitors identi-fied as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016;239(3):320-334. google scholar
• 100. Alholle A, Brini AT, Bauer J, et al. Genome-wide DNA methy-lation profiling of recurrent and non-recurrent chordomas. Epi-genetics. 2015;10(3):213-220. google scholar
• 101. Otani R, Mukasa A, Shin M, et al. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. J Neurosurg. 2018;128(5):1428-1437. google scholar
• 102. Li G, Cai L, Zhou L. Microarray gene expression profiling and bioinformatics analysis reveal key differentially expressed genes in clival and sacral chordoma cell lines. Neurol Res. 2019;41(6):554-561. google scholar
• 103. Liang C, Ma Y, Yong L, et al. Y-box binding protein-1 pro-motes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma. Cancer Sci. 2019;110(1):166-179. google scholar
• 104. Ricci-Vitiani L, Runci D, D’Alessandris QG, et al. Chemother-apy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. Neoplasia. 2013;15(7):773-782. google scholar
• 105. Wang K, Tian K, Wang L, et al. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas. Mol Med Rep. 2015;12(3):4298-4304. google scholar
• 106. Jahanafrooz Z, Stallinger A, Anders I, et al. Influence of silibinin and p-p -dimethylacrylshikonin on chordoma cells. Phytomedicine. 2018;49:32-40. google scholar
• 107. Lee DH, Zhang Y, Kassam AB, et al. Combined PDGFR and HDAC inhibition overcomes PTEN dis-ruption in Chordoma. PLoS One. 2015;10(8):e0134426. doi:10.1371/journal.pone.0134426. google scholar
• 108. Davies JM, Robinson AE, Cowdrey C, et al. Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. J Neurosurg. 2014;120(2):331-336. google scholar
• 109. Burger A, Vasilyev A, Tomar R, et al. A zebrafish model of chor-doma initiated by notochord-driven expression of HRASV12. Dis Model Mech. 2014;7(7):907-913. google scholar
• 110. Lebellec L, Chauffert B, Blay JY, et al. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sar-coma Group (GSF/GETO) and the Association des Neuro-Oncologues d’Expression Française (ANOCEF). EurJ Cancer. 2017;79:119-128. google scholar
• 111. Stacchiotti S, Morosi C, Lo Vullo S, et al. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. Cancer. 2018;124(20):4056-4063. google scholar
• 112. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D1082. google scholar
• 113. Harding SD, Armstrong JF, Faccenda E, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials. Nucleic Acids Res. 2022;50(D1):D1282-D1294. google scholar